Evidence map›Paper›PMID 42352288›Full record

ArticleBiomolecules2026

Unmasking Indolent Systemic Mastocytosis in Patients with Unexplained or Treatment-Refractory Osteoporosis: A Case Series with Diagnostic and Therapeutic Implications.

Lucia Jankovski, Rok Herman, Matej Rakusa, Peter Kopač, Mark Kačar, Matevž Škerget, Andrej Janež, Mojca Jensterle

Abstract readCase Reports
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lucia JankovskiDepartment of Internal Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
Rok HermanDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
Matej RakusaDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-8044-3527
Peter KopačFaculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0001-7261-6689
Mark KačarFaculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0003-2035-6998
Matevž ŠkergetFaculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-6283-9720
Andrej JanežDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-6594-5254
Mojca JensterleDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-8861-8803

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indolent systemic mastocytosis (ISM) is an under-recognised cause of secondary osteoporosis, and skeletal fragility may be the only presenting feature, delaying diagnosis. We describe four adults referred to a tertiary endocrinology service for unexplained osteoporosis or low-trauma fractures, in whom systemic mastocytosis (SM) was identified during work-up. All had elevated basal serum tryptase (41.4-87.0 µg/L), bone-marrow biopsy showing atypical mast cells and the

Indexed as

Mastocytosis, SystemicOsteoporosisAdultAgedFemaleHumansMaleMiddle AgedProto-Oncogene Proteins c-kitTryptasesZoledronic AcidProto-Oncogene Proteins c-kitTryptasesZoledronic Acidavapritinibbone mineral densitybone turnover markersfragility fractureindolent systemic mastocytosisKIT D816Vosteoporosissecondary osteoporosisserum tryptasezoledronic acid

Identifiers

PMID42352288
PMCPMC13297382

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.